Spring til hovednavigation Spring til søgning Spring til hovedindhold

Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest

17 Citationer (Scopus)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest'. Sammen danner de et unikt fingeraftryk.
Sorter

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology